Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PROTACs as Potential Therapeutic Agents for Cancer Drug Resistance

29 Oct 2019

Abstract excerpt

Cancer drug resistance has become the major problem facing current clinical treatment via different kinds of therapies. Proteolysis targeting chimeras (PROTACs) as a novel and powerful strategy have attracted a great deal of attention both from academia and from industry for their sensitivity to drug-resistant targets relying on their unique characteristics compared to those of traditional inhibitors. PROTACs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31661257
DOI: 10.1021/acs.biochem.9b00848

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PROTACs as Potential Therapeutic Agents for Cancer Drug ResistancePMID 31661257Read ↗

Overcoming Cancer Drug Resistance Utilizing PROTAC TechnologySemantic proximity Read ↗

Targeting the Interplay of Proteins through PROTACs for the Management of Cancer and Associated DisordersSemantic proximity Read ↗

PROTACs: great opportunities for academia and industrySemantic proximity Read ↗

PROTAC’ing oncoproteins: targeted protein degradation for cancer therapySemantic proximity Read ↗

New-generation advanced PROTACs as potential therapeutic agents in cancer therapySemantic proximity Read ↗

Progress in RAS-targeted therapeutic strategies: From small molecule inhibitors to proteolysis targeting chimeras.Semantic proximity Read ↗

Proteolysis Targeting Chimera Agents (PROTACs): New Hope for Overcoming the Resistance Mechanisms in Oncogene-Addicted Non-Small Cell Lung CancerSemantic proximity Read ↗

The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cellsSemantic proximity Read ↗

PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat CancerSemantic proximity Read ↗

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?Semantic proximity Read ↗

Progress of small molecules for targeted protein degradation: PROTACs and other technologiesSemantic proximity Read ↗

[Research Progress of Proteolysis Targeting Chimeria in NSCLC Therapy].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.